TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.

Eyal C Attar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.